Immunotherapy in EGFR-TKI-resistant NSCLC: Mechanisms, therapeutic strategies, and emerging challenges
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-04 · 1881 (2) · 189561
DOI: 10.1016/j.bbcan.2026.189561 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-04. Verfasst von Shuyi Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: Jiangsu Cancer Hospital, Science and Technology Development Fund, National Natural Science Foundation of China.
Abstract (Originalsprache)
The epidermal growth factor receptor (EGFR) mutation represents one of the most prevalent driver gene alterations in non-small cell lung cancer (NSCLC) patients. EGFR tyrosine kinase inhibitors (EGFR-TKIs), particularly third-generation agents, have emerged as the top priority for patients harboring activating mutations. This review commences with a concise introduction to the EGFR-mutated tumor microenvironment and its dynamic changes associated with EGFR-TKI administration. We systematically summarize current therapeutic options for patients who progress on EGFR-TKIs, providing an overview of immunotherapy resistance mechanisms and corresponding management strategies. Finally, this review discusses the progression patterns and subsequent therapies in patients pretreated with EGFR-TKIs who develop resistance to immunotherapy. A treatment algorithm structured around resistance typology, molecular profiling, and progression patterns provides substantial clinical value for guiding therapeutic decisions in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
- Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China. Electronic address: wangxiaohua@jszlyy.com.cn.
- Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China. Electronic address: zhouguoren888@163.com.
Förderung
- Jiangsu Cancer Hospital
- Science and Technology Development Fund
- National Natural Science Foundation of China
Zitieren
APA
Hu, S., Shi, X., Hu, Q., Wang, X., & Zhou, G. (2026). Immunotherapy in EGFR-TKI-resistant NSCLC: Mechanisms, therapeutic strategies, and emerging challenges. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(2), 189561. https://doi.org/10.1016/j.bbcan.2026.189561
Vancouver
Hu S, Shi X, Hu Q, Wang X, Zhou G. Immunotherapy in EGFR-TKI-resistant NSCLC: Mechanisms, therapeutic strategies, and emerging challenges. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(2):189561. doi:10.1016/j.bbcan.2026.189561
BibTeX
@article{Hu2026,
author = {Hu, Shuyi and Shi, Xinhong and Hu, Qin and Wang, Xiaohua and Zhou, Guoren},
title = {Immunotherapy in EGFR-TKI-resistant NSCLC: Mechanisms, therapeutic strategies, and emerging challenges},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {2},
pages = {189561},
doi = {10.1016/j.bbcan.2026.189561}
}
EUVIMED